Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawata, S, Yamasaki, E, Nagase, T, Inui, Y, Ito, N, Matsuda, Y, Inada, M, Tamura, S, Noda, S, Imai, Y, Matsuzawa, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363838/
https://www.ncbi.nlm.nih.gov/pubmed/11286466
http://dx.doi.org/10.1054/bjoc.2000.1716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363838/
https://www.ncbi.nlm.nih.gov/pubmed/11286466
http://dx.doi.org/10.1054/bjoc.2000.1716

Ejemplares similares